- Home
- XHLD vs CGTX Comparison
XHLD vs CGTX Comparison
Compare XHLD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHLD
- CGTX
- Stock Information
- Founded
- XHLD 2011
- CGTX 2007
- Country
- XHLD United States
- CGTX United States
- Employees
- XHLD N/A
- CGTX N/A
- Industry
- XHLD
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- XHLD
- CGTX Health Care
- Exchange
- XHLD NYSE
- CGTX Nasdaq
- Market Cap
- XHLD 17.6M
- CGTX 20.5M
- IPO Year
- XHLD 2025
- CGTX 2021
- Fundamental
- Price
- XHLD $0.43
- CGTX $0.26
- Analyst Decision
- XHLD Strong Buy
- CGTX Strong Buy
- Analyst Count
- XHLD 1
- CGTX 5
- Target Price
- XHLD $8.00
- CGTX $5.63
- AVG Volume (30 Days)
- XHLD 665.4K
- CGTX 1.8M
- Earning Date
- XHLD 05-20-2025
- CGTX 08-07-2025
- Dividend Yield
- XHLD N/A
- CGTX N/A
- EPS Growth
- XHLD N/A
- CGTX N/A
- EPS
- XHLD N/A
- CGTX N/A
- Revenue
- XHLD $3,115,000.00
- CGTX N/A
- Revenue This Year
- XHLD $42.64
- CGTX N/A
- Revenue Next Year
- XHLD $65.31
- CGTX N/A
- P/E Ratio
- XHLD N/A
- CGTX N/A
- Revenue Growth
- XHLD N/A
- CGTX N/A
- 52 Week Low
- XHLD $0.40
- CGTX $0.22
- 52 Week High
- XHLD $8.54
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- XHLD N/A
- CGTX 37.68
- Support Level
- XHLD N/A
- CGTX $0.29
- Resistance Level
- XHLD N/A
- CGTX $0.32
- Average True Range (ATR)
- XHLD 0.00
- CGTX 0.03
- MACD
- XHLD 0.00
- CGTX 0.00
- Stochastic Oscillator
- XHLD 0.00
- CGTX 12.50
About XHLD TEN HOLDINGS INC
TEN Holdings Inc is a provider of event planning, production, and broadcasting services. The company produces virtual and hybrid events and physical events. Virtual and hybrid events involve virtual and hybrid event planning, production and broadcasting services, and continuing education services, all of which are supported by its Xyvid Pro Platform. Physical events involve live streaming and video recording of physical events. The Company operates business as one operating segment which includes two revenue types: Hybrid and Virtual Events and Physical Events.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.